Introduction {#s1}
============

Respiration is a complex function controlled in large part by raphe serotonergic (5-HT) neurons ([@bib52]). Central 5-HT depletion induces severe apneas during the early postnatal period ([@bib6]; [@bib54]) and serotonopathy is implicated in the genesis of breathing disorders in human pathologies including neurodevelopmental diseases such as Sudden Infant Death Syndrome ([@bib11]; [@bib19]; [@bib23]; [@bib39]), Rett syndrome ([@bib1]; [@bib53]) and Prader-Willi Syndrome (PWS) ([@bib57]). However, the cellular and molecular events that underlie serotonopathy, and the causal link between serotonopathy and respiratory dysfunction in these pathologies are poorly understood.

PWS (prevalence 1/20000) is characterized by a combination of endocrine, metabolic, cognitive and behavioural/psychiatric symptoms (OMIM \#176270). Its associated respiratory disturbances ([@bib31]; [@bib35]; [@bib50]) are highly disruptive to the daily life of patients and represent the most common cause of death (73% of infants and 26% of adults) ([@bib9]). They include both obstructive ([@bib13]; [@bib40]) and central sleep apneas {[@bib13] \#1495; [@bib48]), and blunted responses to hypercapnia/hypoxia possibly due to a lack of chemoreceptor sensitivity ([@bib5]; [@bib16]; [@bib45]; [@bib14]). Central apneas are present at birth ([@bib57]) and are prevalent throughout infancy while obstructive sleep apneas are more frequent in adolescents ([@bib10]).

PWS is caused by the loss of paternal expression of several genes of the 15q11-q13 region, including *NECDIN.* Necdin protein is a member of the Mage family, with proposed functions in differentiation ([@bib4]; [@bib49]), migration ([@bib24]; [@bib32]; [@bib51]), neurite growth ([@bib28]; [@bib51]), axonal extension, arborization and fasciculation ([@bib37]), and cell survival ([@bib2]; [@bib3]; [@bib25]; [@bib51]). Among several mouse models of PWS, only those with Necdin deletion, *Necdin (Ndn)*-KO mouse models (*Ndn^tm1-Stw^* \[[@bib17]\] and *Ndn^tm1-Mus^* \[[@bib34]\]), present breathing deficits. Newborns *Ndn*-KO showed severe arhythmia, apnea, and blunted responses to respiratory challenges that frequently result in early postnatal lethality ([@bib42]; [@bib57]). This dyspnoeic phenotype is recapitulated in brainstem slices that contain the Inspiratory Rhythm Generator (IRG), which display an irregular inspiratory rhythm and apneas ([@bib42]; [@bib57]). Interestingly, 5-HT application, as well as other neuromodulators that are commonly co-released by medullary 5-HT neurons, such as substance P and thyrotropin-releasing hormone ([@bib20]; [@bib21]; [@bib22]; [@bib41]), stabilized the in vitro inspiratory rhythm ([@bib37]; [@bib57]).

A role for serotonergic transmission in the genesis of respiratory dysfunction in the *Necdin*-KO model is supported by neuroanatomical studies: Pagliardini and colleagues report abnormal morphology and orientation of axonal fibers that contain large 5-HT/Substance P varicosities in the developing *Ndn^tm1-Stw^*-KO medulla ([@bib37]; [@bib38]). Similarly, we have also previously found that 5-HT fibers contained 'swollen 5-HT varicosities' in the *Ndn^tm1-Mus^*-KO model, and that *Necdin* is expressed in virtually all 5-HT neurons ([@bib57]).

These findings suggest a potential role for abnormalities in 5-HT metabolism and release as a potential mediator of respiratory dysfunction in the *Necdin*-KO model of PWS, but fall short of proving causality. Here, we demonstrate a causal link between the perturbed development of the 5-HT system in *Ndn^tm1-Mus^*-KO mice (referred to hereafter as *Ndn*-KO) and their observed respiratory phenotype (central apnea and hypercapnia). Our data implicate increased activity of serotonin transporter (SERT) as a key mediator of central apnea in this model, and that its inhibition restores normal breathing in *Ndn*-KO mice.

Results and discussion {#s2}
======================

Lack of Necdin affects the development and function of 5-HT neurons {#s2-1}
-------------------------------------------------------------------

Pet-EYFP mice expressing YFP under Pet1-promoter control, an early marker of developing 5-HT neurons ([@bib18]), were used to show that Necdin is expressed from E10.5 in early post-mitotic 5-HT precursors and later on in all 5-HT neurons until adulthood ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A--I](#fig1s1){ref-type="fig"}).

![Necdin expression in 5-HT neurons and alterations of 5-HT neuronal development and activity in *Ndn*-KO mice.\
(**A**) Scheme adapted from ([@bib18]) representing expression profiles of Necdin (green), Pet1 (blue) and 5-HT (red) throughout embryonic development of 5-HT neurons as soon as the progenitors become post-mitotic and start their radial migration by successive waves between E11.5 and E13.5. (**B--C**) 5-HT immunolabelling of brainstem sagittal sections of WT and *Ndn*-KO at E16.5. (**B**) 5-HT nuclei: B4 to B9 (left panels) or B1-B2 (right panels) are abnormal in *Ndn*-KO compared to WT. (**C**) Quantification of 5-HT neurons in the B1-B2 raphe nuclei (WT: 1836 (1751, 1878), n = 8; *Ndn-*KO: 1312 (1234, 1384), n = 7; MW, p=0.0003). (**D--E**) (**D**) Brainstem coronal sections of *Pet-EYFP* neurons from E11.5 WT and *Ndn*-KO mice illustrating radial migration from the ventricular zone (**V**) to the pial surface. (**E**) Quantification of nonlinear migration by measuring the α angle (10 cells/mouse) between the ventricular process and a virtual axis crossing the two opposing points from which neurites extend from the soma: (Angle (°): WT: 1.1(0.5, 3.5), n = 4; *Ndn-*KO: 18(2.8, 93.5), n = 3; MW, p\<0.0001). (**F--H**) Confocal time-lapse analyses of cell migration of *Pet-EYFP* and *Pet-EYFP*/*Ndn*-KO neurons. (**F**) Plots representing the coordinates of individual cell bodies over time illustrate different cell migration patterns in WT (n = 4) and *Ndn-*KO (n = 3) *Pet-EYFP* neurons (11 cells/mouse). (**G**) Tortuosity index was increased by 52% in *Ndn-*KO compared to WT mice (WT: 1.08(1.01, 1.26); *Ndn-*KO: 1.65(1.36, 1.93); MW, p=0.0005). (**H**) Velocity was decreased by 37% in *Ndn-*KO compared to WT (Velocity (µm.s^−1^): WT: 2.50 10^−3^ (2.00, 2.93); *Ndn-*KO: 1.57 10^−3^ (1.09, 2.00); MW, p\<0.0001). (**I--K**) Current clamp recordings of *Pet-EYFP* neurons (2 cells/slice) in WT (n = 3) and *Ndn-*KO (n = 3) brain slices. (**I**) Spontaneous discharge pattern of *Pet-EYFP* neurons; (**J--K**) Firing rate (**J**) and resting membrane potential (**K**) in *Ndn-*KO cells and aged-matched WT controls. Frequency (Hz): WT: 2.50(1.20, 2.50); *Ndn-*KO (4.60(4.00, 7.90); MW, p=0.0025; Voltage (mV): WT: −44.37(-46.25, --43.76); *Ndn-*KO: −42.64(-43.03, --42.55); MW test, p=0.0002.](elife-32640-fig1){#fig1}

We then assessed whether Necdin deficiency could induce alterations of 5-HT neuronal development. In wild-type mice rostral hindbrain 5-HT neurons project to the mesencephalon at E12.5, and we observed a decrease in those ascending 5-HT projections in *Ndn*-KO embryos ([Figure 1---figure supplement 1J](#fig1s1){ref-type="fig"}), confirming previous work ([@bib38]). At E16.5, when the 5-HT raphe nuclei reach their mature configuration, we observed misplaced 5-HT neurons in *Ndn-*KO embryos ([Figure 1B](#fig1){ref-type="fig"}), with \~30% reduction in the total number of 5-HT neurons in the B1-B2 caudal raphe nuclei at birth ([Figure 1C](#fig1){ref-type="fig"}).

Our observations suggested a defect in 5-HT neuronal migration; which was tested using the *Pet-EYFP* model. In E10.5 WT embryos, Pet-EYFP neurons displayed typical bipolar morphology with oval-shaped somata aligned with two primitive processes attached to the ventricular and pial surfaces, required for somal translocation and involved in migration processes ([@bib18]) ([Figure 1D](#fig1){ref-type="fig"}). In contrast cells were not correctly aligned and process orientation was significantly disturbed in *Pet-EYFP/Ndn-*KO embryos ([Figure 1D--E](#fig1){ref-type="fig"}). Cell migration was also defective in organotypic slice cultures prepared from E12.5 embryos. Two-photon time-lapse imaging indicated that migratory behavior, based on somal translocation, was altered in *Ndn*-KO mice ([Figure 1F--H](#fig1){ref-type="fig"}, [Figure 1---video 1](#fig1video1){ref-type="video"} and [2](#fig1video2){ref-type="video"}) with tracked cells exhibiting increased tortuosity ([Figure 1G](#fig1){ref-type="fig"}) and decreased velocity ([Figure 1H](#fig1){ref-type="fig"}) of their growth trajectories. Interestingly, a comparable migration defect has been described in primary cultures of *Ndn^tm1-Stw^*-KO cortical neurons ([@bib8]) Here we revealed an alteration of cell migration of 5-HT precursors leading to misplaced 5-HT raphe nuclei in *Ndn*-KO mice.

The acquisition of specific firing properties is considered a critical marker of 5-HT neuronal and circuit maturation ([@bib44]). Using visually guided patch-clamp recordings on brain slices (P15), we demonstrated a significant increase of spontaneous firing in *Pet-EYFP/Ndn*-KO cells ([Figure 1I--K](#fig1){ref-type="fig"}) suggesting a decreased availability of extracellular 5-HT ([@bib29]). Overall, our results show that Necdin is responsible for the normal migration of 5-HT precursor neurons during development and exerts effects on their electrophysiological properties in post-natal life.

Lack of Necdin increases the expression and activity of serotonin transporter {#s2-2}
-----------------------------------------------------------------------------

We hypothesised that reduced availability of extracellular 5HT could have contributed to the excessive electrophysiological activity we observed in Pet-EYFP neurons in *Ndn-*KO animals and examined potential mechanisms through which extracellular 5-HT could be reduced. We compared the distributions of 5-HT- immunoreactive enLarged Punctiform Axonal stainings (5-HT LPAs, previously named 'swollen large varicosities' \[[@bib37]; [@bib57]\]) in *Ndn-*KO and WT mice. In all regions analyzed we found significantly more 5-HT LPAs in *Ndn-*KO mice ([Figure 2A--B](#fig2){ref-type="fig"}). These 5-HT LPAs could result from (1) an increase of 5-HT synthesis and/or (2) a decrease in 5-HT degradation and/or (3) an increase of 5-HT reuptake. HPLC analyses showed a similar level of L-Trp and 5-HT in *Ndn*-KO compared with WT mice, but a significant increase of 5HIAA product in mutants (the ratio of 5HIAA/5-HT also being increased: [Figure 2---figure supplement 1A--D](#fig2s1){ref-type="fig"}). Noticeably, transcript levels of Tryptophan hydroxylase 2, the enzyme that converts L-Trp to 5-HT, were similar in *Ndn*-KO and WT mice ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). These results suggest that the increase in 5-HT LPAs found in *Ndn*-KO brainstems probably result from an accumulation of intracellular 5-HT due to an increased 5-HT reuptake, since there is no increase of 5-HT synthesis but, on the contrary, an increase of 5-HT degradation.

![Large punctiform axonal 5-HT staining (5-HT LPAs) results from an increase in SERT expression and activity in *Ndn*-KO mice.\
(**A--B**) (**A**) Axonal 5-HT immunoreactivity illustrating 5-HT LPAs in the raphe of WT, *Ndn*-KO, *Slc6a4*-KO and *Ndn/Slc6a4-*DKO neonates (P1). (**B**) 5-HT LPAs were counted for all different genotypes (n = 3/genotype) in the raphe nuclei (B1--B2, B3, B7, B9), cortex and hippocampus.: Raphe B1-B2: WT: 2.2 ± 0.4; *Ndn*-KO: 11.8 ± 0.8, p=0.003; Raphe B3: WT: 2.6 ± 0.8; *Ndn*-KO: 9.3 ± 1.6, p=0.01; Raphe B7: WT: 6.5 ± 1.2; *Ndn*-KO: 15.5 ± 2.6, p=0.07; Raphe B9: WT: 5.1 ± 2.72; *Ndn*-KO: 14.6 ± 2.9, p=0.0001; Cortex: WT: 5.9 ± 2.0; *Ndn*-KO: 13.4 ± 0.8, p=0.01; Hippocampus: WT: 4.5 ± 1.2; *Ndn*-KO: 11.8 ± 2.5, p=0.01. p-values determined by two-way ANOVA followed by Bonferroni post-hoc test. DKO: double KO. Bar graphs represent mean ±SEM. (**C--D**) (**C**) Western blot analysis of SERT protein expression in brainstem collected from WT, *Ndn*-KO and *Slc6a4-*KO (negative control) neonates (P1). (**D**) Quantification of SERT expression normalized to β3 tubulin expression: WT: 0.45 (0.29, 0.56), n = 5; *Ndn*- KO: 1.11 (0.75, 1.68), n = 4; MW, p=0.016). Scatter dot plots, report Q2 (Q1, Q3). (**E--H**) Real time and single living cell analyses of SERT uptake activity using the fluorescent substrate ASP+, a fluorescent substrate of SERT. (**E**) Kinetic experiment recordings of accumulation of ASP+ over time (5 min recording). Coefficient of Determination R^2^: WT = 0.97; *Ndn* KO = 0.99; *Slc6a4-*KO = 0.93. Mean velocity (v) of ASP+ accumulation obtained by linear regression analyses of the slopes: (AUF.s^−1^): WT: 0.36 ± 0.01, n = 18; *Ndn-KO*: 0.51 ± 0.01, n = 18, covariance (ANCOVA), p\<0.0001. Non-specific accumulation of ASP+ fluorescence was evaluated in *Slc6a4*-KO neurons and found to be strongly low (0.02 ± 0.01 (n = 6 cells). (**F**) Saturation experiments using gradual concentration of APS+. Non-linear curve-fitting yielded a one-phase exponential association, with a Vmax (**G**) and Km (**H**): Vmax (AUF.s^−1^): WT: 0.45 ± 0.05, n = 64; *Ndn-*KO: 0.84 ± 0.12, n = 67; *Slc6a4-*KO: 0.01 ± 0.03, n = 37, p\<0.0001; Km (µM): WT: 6.03 ± 1.60, n = 64; *Ndn*-KO: 12.03 ± 3.55, n = 67; *Slc6a4-*KO: 1.83 ± 1.60, n = 37, p\<0.0001. AUF: arbitrary unit of fluorescence. p-values determined by K-W test, followed by Dunn post-hoc test. Bar graphs represent mean ±SEM. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001. Scatter dot plots, report Q2 (Q1, Q3). \*\*p\<0.01; \*\*\*p\<0.001.](elife-32640-fig2){#fig2}

We hypothesised that overexpression of serotonin transporter (SERT) represents a plausible mechanism through which 5-HT could be accumulated in *Ndn*-KO mice, based on the observation that inactivation of *Maged1*, another member of the *Mage* gene family, leads to overexpression of SERT (encoded by the *Slc6a4* gene) ([@bib33]). Indeed, we observed a 3.2 fold increase in SERT protein expression in the brainstems of *Ndn*-KO compared to WT pups ([Figure 2C--D](#fig2){ref-type="fig"}), while *Slc6a4* transcript levels were similar ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}). This suggests post-transcriptional or post-translational dysregulation of *Slc6a4/*SERT in *Ndn*-KO. Subsequently, in 5-HT neurons of raphe primary cultures, we assessed SERT activity by live single cell uptake assay, using ASP+ (4(4-(dimethylamino)styryl)-N-methylpyridinium), a fluorescent substrate of SERT ([@bib26]; [@bib36]). Changes in the kinetics and saturation of ASP+ uptake were measured after 8 days in vitro culture in 5-HT neurons from neonatal (P0) WT, *Ndn-*KO, and *Slc6a4*-KO mice ([Figure 2E--H](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2A--B](#fig2s2){ref-type="fig"}). As expected, cultures accumulated ASP+ over time in all conditions tested. However, kinetics experiments show that ASP+ accumulation was significantly faster (greater mean velocity v) in *Ndn-KO* compared to WT raphe neurons ([Figure 2E](#fig2){ref-type="fig"}). Saturation experiments using increasing concentrations of ASP+ confirmed that ASP+ uptake is a saturable process ([Figure 2F](#fig2){ref-type="fig"}) and showed a Vmax ([Figure 2G](#fig2){ref-type="fig"}) and KM ([Figure 2H](#fig2){ref-type="fig"}) significantly higher in *Ndn*-KO than in WT or *Slc6a4*-KO neurons. ASP+ uptake was \~2 fold increased in *Ndn*-KO while it was null in *Slc6a4*-KO cell cultures. We conclude that there is an increase of ASP+ uptake in *Ndn*-KO neurons, specifically dependent on SERT activity, suggesting a mechanism for 5-HT LPAs accumulation in vivo. To determine whether in vivo deletion of *Slc6a4* could suppress the 5-HT LPAs in *Ndn-*KO, we compared the number of 5-HT LPAs in *Ndn*-KO, *Slc6a4*-KO and *Ndn/Slc6a4*-double KO (*Ndn/Slc6a4-*DKO) neonates in various brain structures. The number of 5-HT LPAs was similar in brains of *Ndn/Slc6a4-*DKO and WT mice ([Figure 2A--B](#fig2){ref-type="fig"}), indicating that the absence of *Ndn* is functionally compensated for by the lack of *Slc6a4*.

Together, our data show that increased SERT expression in *Ndn*-KO mice underlies an increase of 5-HT reuptake, which accumulates in 5-HT LPAs. In the absence of any increase in 5-HT synthesis (and in fact increased 5-HT degradation), this sequence of events could be sufficient to cause a physiologically relevant decrease extracellular 5-HT.

Genetic ablation or pharmacological inhibition of SERT uptake restores normal breathing in *Ndn-*KO mice {#s2-3}
--------------------------------------------------------------------------------------------------------

As exogenous 5-HT application stabilized respiratory rhythm of *Ndn*-KO mice in vitro, ([@bib57]), we hypothesized that SERT dysregulation observed in *Ndn-*KO mice might underlie their respiratory phenotype. To further investigate this causal link, we compared breathing parameters in WT, *Ndn-*KO, *Ndn/Slc6a4-*DKO and in *Ndn-*KO pups treated with Fluoxetine, a selective 5-HT reuptake inhibitor (SSRI) used clinically to increase extracellular 5-HT ([Figure 3A--B](#fig3){ref-type="fig"}). First, we confirmed that respiratory deficits, quantified as the percentage of mice exhibiting apnea ([Figure 3C](#fig3){ref-type="fig"}), the number of apneas per hour ([Figure 3D](#fig3){ref-type="fig"}), or the accumulated apnea duration ([Figure 3E](#fig3){ref-type="fig"}), were significantly increased in *Ndn*-KO compared to WT mice. These deficits were suppressed by reducing SERT function either by constitutive genetic inactivation (*Ndn/Slc6a4-*DKO pups) or by 10 days of Fluoxetine treatment (P5-P15; 10 mg/kg/day) in *Ndn-*KO pups ([Figure 3C--E](#fig3){ref-type="fig"}). Other basic respiratory parameters (minute ventilation, frequency of breathing, tidal volume) were unchanged between all genotypes ([Figure 3F--H](#fig3){ref-type="fig"}). Therefore, our results show that increasing extracellular 5-HT is sufficient to suppress apneas in juvenile *Ndn*-KO mice.

![Genetic ablation or pharmacologic inhibition of SERT suppresses apnea and rescues central chemoreflex in *Ndn*-KO mice.\
(**A**) Workflow experiment of constant airflow whole body plethysmography performed in unanaesthetized, unrestrained WT, *Ndn-KO*, *Ndn/Slc6a4*-DKO and *Ndn-KO+Fluox* mice at the age of P15. *Ndn*-KO and WT animals (indicated here and in the figure as WT or *Ndn*-KO) have been pre-treated with 0.9% NaCl from age P5 to P15. *Ndn-KO* mice (indicated here and in the figure as *Ndn*-KO+Fluox) have been pre-treated with with Fluoxetine (10 mg/Kg/day) from age P5 to P15. (**B**) Plethysmographic recordings of WT, *Ndn*-KO, *Ndn/Slc6a4*-DKO and *Ndn*-KO+Fluox mice at the age of P15. (**C--E**) Quantification of apnea in P15 mice. (**C**) Proportion of apneic mice: WT: 2 of 8; *Ndn*-KO: 7 of 8; corresponding respectively to 25% and 87%; Chi^2^ test, p=0.01. Genetic ablation of *Slc6a4*or early Fluoxetine treatment normalized the number of *Ndn-KO* apneic mice: *Ndn/Slc6a4* DKO: 2 of 8, 25%; Chi^2^ test, p\>0.99, N.S.; *Ndn*-KO+Fluox: 2 of 8, 25%; Chi^2^ test, p\>0.99, N.S. (**D**) Number of apnea in *Ndn-KO* compared to WT mice: WT: 0.0 (0.0, 1.5), n = 8; *Ndn*-KO: 3.8 (2.0, 8.0), n = 8; p=0.01. Genetic ablation of *Slc6a4* or Fluoxetine treatment normalized the number of apnea of *Ndn-*KO mice to WT values: *Ndn/Slc6a4-*DKO: 0.0 (0.0, 2.0), n = 8; p\>0.99, N.S.; *Ndn*-KO+Fluox: 0.0 (0.0, 2.2), n = 8; p\>0.99, N.S. p-values determined by KW test followed by Dunn post-hoc test with comparison to WT. (**E**) Cumulative distribution of apnea (number of cumulated values) over apnea duration (msec) in WT, *Ndn*-KO, *Ndn/Slc6a4*-DKO and *Ndn*-KO treated by Fluoxetine. Compared to WT, *Ndn*-KO mice demonstrated a significant increase of cumulative apnea both in term of number and duration (Kolmogorov-Smirnov test, p=0.01). However, such increase was normalized to WT after genetic deletion of *Slc6a4* or Fluoxetine treatment. (**F--H**) Basic breathing parameters: (**F**) Minute ventilation, VE (the total volume breathed over one min): WT: 24.5 (17.7, 32.7), n = 8; *Ndn*-KO: 17.5 (15.2, 18.7), n = 8; p=0.14, N.S.; *Ndn/Slc6a4*-DKO: 18.0 (17.0, 20.0), n = 8; p=0.25, N.S. and *Ndn*-KO+Fluox: 21.0 (18.2, 29.7), n = 8; p\>0.99, N.S.. (**G**) Frequency of breathing, Rf (breaths/min): WT: 338 (312, 3867), n = 8; *Ndn*-KO: 296 (270, 352), n = 8; p=0.56, N.S.; *Ndn/Slc6a4*-DKO: 292 (2890, 305), n = 8; p=0.16, N.S. and *Ndn*-KO+Fluox: 329 (289, 388), n = 8; p\>0.99, N.S. (**H**) Tidal Volume, VT (the volume flow per breath): WT: 0.07 (0.05, 0.09), n = 8; *Ndn*-KO: 0.06 (0.06, 0.06), n = 8; p=0.38, N.S.; *Ndn/Slc6a4*-DKO: 0.06 (0.05, 0.07), n = 8; p=0.51, N.S. and *Ndn*-KO+Fluox: 0.07 (0.06, 0.08), n = 8; p\>0.99, N.S. p-values determined by K-W test followed by Dunn post-hoc test with comparison to WT.Scatter dots represent Q2 (Q1, Q3). N.S.: non-significant; \*p\<0.05.](elife-32640-fig3){#fig3}

Since Fluoxetine treatment in early life has positive effects on apneas, we next questioned the long-term consequences of this treatment. Novel cohorts of WT, *Ndn-*KO and *Ndn-*KO pups were treated as above with Fluoxetine or vehicle and then submitted to plethysmography 0, 15 and 45 days after treatment (DAT) ([Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}). The positive effect of Fluoxetine on respiratory function in *Ndn-*KO pups at the end of treatment were confirmed in this cohort, but did not persist at 15 and 45 DAT ([Figure 3---figure supplement 1C--E](#fig3s1){ref-type="fig"}). Other respiratory parameters (minute ventilation, frequency of breathing, tidal volume) measured at 45 DAT were unchanged between all genotypes ([Figure 3---figure supplement 1F--H](#fig3s1){ref-type="fig"}).

An altered ventilatory response to hypercapnia was previously observed in adult *Ndn-*KO mice ([@bib57]), so we next investigated whether this deficit is apparent in P0-P1 pups. We examined the chemoreflex of *Ndn-*KO and WT neonates by initially subjecting them to a moderate hypercapnia (5 min; 4% CO~2~) ([Figure 4A--C](#fig4){ref-type="fig"}). Under hypercapnic stress, WT but not *Ndn-*KO neonates progressively increased their respiratory frequency (Rf) ([Figure 4D](#fig4){ref-type="fig"}), leading to an increase in minute ventilation (volume breathed over 1 min,VE) ([Figure 4F](#fig4){ref-type="fig"}). In contrast, no significant effects of hypercapnia were detected on any respiratory variables in *Ndn*-KO pups and thus *Ndn-*KO pups appear relatively insensitive to hypercapnia. To determine whether altered central 5-HT transmission contributes to this effect, we performed electrophysiological recordings of rhythmic phrenic bursts using *en bloc* brainstem-spinal cord preparations from P0-P1 WT and *Ndn*-KO pups. During perfusion with physiological aCSF (pH 7.4), we found no significant difference in phrenic burst (PB) shape, amplitude or discharge frequency (PBf) between WT and *Ndn*-KO pups ([Figure 4G--H](#fig4){ref-type="fig"}). As expected, PBf in WT preparations progressively increased upon acidosis (pH = 7.1, [Figure 4I,L](#fig4){ref-type="fig"}). However, this effect was not observed in *Ndn*-KO preparations ([Figure 4J,L](#fig4){ref-type="fig"}).

![Alteration of respiratory chemoreflex in *Ndn*-KO neonates is rescued by Fluoxetine.\
(**A--F**) Effect of hypercapnia on in vivo ventilatory parameters of WT and *Ndn*-KO neonates. (**A**) Workflow experiment of constant airflow whole body plethysmography performed in unanaesthetized, unrestrained WT, *Ndn-KO* neonates at P0-P1 when breathing either air or hypercapnic mixture containing 4% CO~2~ in air for 5 min. Data for analyses were collected in the last 5 min (air) or the last min (hypercapnia). (**B--C**) (**B**) Plethysmographic recordings of WT and *Ndn*-KO neonates when breathing air or (**C**) at 5th min upon hypercapnic respiratory challenge. (**D**) Respiratory frequency (Rf) in WT and *Ndn*-KO pups when subjected to hypercapnic stress: WT Air: 91 ± 8; WT hypercapnia: 163 ± 16; n = 8, p=0.004; *Ndn*-KO Air: 95 ± 12; *Ndn*-KO hypercapnia: 123 ± 11; n = 8, p=0.31, N.S. p-values determined by two-way-ANOVA test followed by Bonferroni post-hoc test. Bar graphs represent mean ±SEM; \*\*p\<0.01; N.S.: non-significant. (**E**) Tidal Volume (VT) (µl.g^−1^) in WT neonates: WT Air: 9 ± 0.7; WT hypercapnia: 12 ± 1; n = 8, p=0.12 N.S.; in *Ndn*-KO: *Ndn*-KO Air: 7.5 ± 0.9; *Ndn*-KO hypercapnia: 10.9 ± 1.1; n = 8, p=0.055. p-values determined by two-way ANOVA test followed by Bonferroni post-hoc test. (**F**) Minute Ventilation (VE) (ml.min^−1^.g^−1^) in WT neonates: WT Air: 0.8 ± 0.1; WT hypercapnia: 2.1 ± 0.1; n = 8, p=0.01; in *Ndn*-KO: *Ndn*-KO Air: 0.7 ± 0.1; *Ndn*-KO hypercapnia: 1.3 ± 0.2; n = 8, p=0.3 N.S. p-values determined by two-way ANOVA test followed by Bonferroni post-hoc test. Bar graphs represent mean ±SEM. \*p\<0.05. (**G--H**) Effect of Fluoxetine treatment on the resting phrenic burst frequency (PBf) and the PBf response to acidosis in *Ndn*-KO medulla preparations. (**G**) Electrophysiological recordings of PBf produced in vitro in WT and *Ndn*-KO *en bloc* brainstem-spinal cord preparations at P0-P1 when superfused first with neutral artificial cerebrospinal fluid (aCSF) (pH 7.4) and then acidified aCSF (pH 7.1). (**H**) Workflow experiment of the electrophysiological recordings on medullary preparations to assess central chemosensitivity in WT and treated with Fluoxetine (20 μM) or untreated *Ndn*-KO mice. (**I--K**) Examples of continuous electrophysiological recordings of rhythmic phrenic bursts produced in *en bloc* brainstem-spinal cord preparations of (**I**) one WT, (**J**) one *Ndn*-KO and (**K**) one *Ndn*-KO treated with Fluoxetine (20 µM) pup and superfused with first neutral aCSF (pH 7.4) (left column recordings) or acidified aCSF (pH 7.1) (right column recordings). (**L**) Quantifications of the resting PBf (c.min^−1^) of *en bloc* preparations superfused with neutral aCSF (pH 7.4) or acidified aCSF (pH 7.1) respectively of WT (WT (pH 7.4): 8.8 c.min^−1^ ±1.2; WT (pH 7.1) 12.8 ± 0.3 c.min^−1^; n = 12, p\<0.001), *Ndn*-KO (*Ndn-*KO (pH 7.4): 9.5 ± 1.0; *Ndn-*KO (pH 7.1): 9.8 ± 0.3 c.min^−1^; n = 12, p=0.41, N.S.) and *Ndn*-KO treated with Fluoxetine: (*Ndn*-KO+Fluox (pH 7.4): 9.6 ± 0.3; *Ndn*-KO+Fluox (pH 7.1): 12.6 ± 0.7; n = 12, p=0.04). Noticeably, under neutral aCSF (pH 7.4) no difference was observed between WT, *Ndn*-KO and *Ndn*-KO+Fluox. However, in acidified aCSF (pH 7.1), Fluoxetine significantly increased the PBf of *Ndn*-KO preparations. p-values determined by two-way ANOVA test followed by Tukey post-hoc test. Bar graphs represent mean ±SEM. N.S: non-significant; \*p\<0.05.\
10.7554/eLife.32640.018Figure 4---source data 1.Plethysmography data before and after hypercapnia in WT and *Ndn*-KO mice.\
10.7554/eLife.32640.019Figure 4---source data 2.Electrophysiology data of rhythmic phrenic bursts frequency during acidosis in WT and *Ndn*-KO preparations - before and after Fluoxetine treatment.\
10.7554/eLife.32640.020Figure 4---source data 3.Relates to [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}.Electrophysiology data of rhythmic phrenic bursts frequency during acidosis in WT and *Ndn*-KO preparations - before and after 8-OHDPAT treatment.](elife-32640-fig4){#fig4}

We then assessed whether increasing extracellular 5-HT could rescue chemoreflex sensitivity in this preparation. Bath application of Fluoxetine (20 µM) prior to acidosis did not affect baseline PBf of *Ndn-*KO preparations ([Figure 4K,L](#fig4){ref-type="fig"}), but instead significantly increased PBf responses to acidosis to levels indistinguishable from WT controls ([Figure 4K,L](#fig4){ref-type="fig"}). Qualitatively similar responses were observed in experiments in which a 5-HT1A receptor agonist (8OHDPAT) was substituted for Fluoxetine ([Figure 4---figure supplement 1A--D](#fig4s1){ref-type="fig"}). We therefore conclude that the central chemoreceptor hyposensitivity characteristic of the *Ndn-*KO model can be restored by pharmacological manipulations that increase extracellular 5-HT and/or stimulate 5-HT1A-R activity.

Early life Fluoxetine-treatment has deleterious long-term respiratory consequences in WT mice {#s2-4}
---------------------------------------------------------------------------------------------

Although Fluoxetine had beneficial but transient effects on apnea incidence in *Ndn-*KO mice, we observed deleterious and long-lasting effects on respiratory function in WT controls. Early life Fluoxetine-treatment induced a significant increase in the number of apneic mice, the frequency of apneas, and the cumulative distribution of apneas at all timepoints measured (0, 15 and 45 DAT, [Figure 3---figure supplement 2A--E](#fig3s2){ref-type="fig"}), such that measurements at 45 DAT in WT mice ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) were similar to those obtained in *Ndn*-KO mice ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The sensitivity of WT brainstem-spinal cord preparations, treated with Fluoxetine or with 8OHDPAT, to acute acidosis was similarly affected ([Figure 4---figure supplement 2A--D](#fig4s2){ref-type="fig"}). In neutral aCSF, neither Fluoxetine ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}) or 8OHDPAT ([Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}) affected resting PBf of WT *en bloc* preparations but instead abolished the normal increases in PBf responses to acidosis. Thus, we confirm that Fluoxetine treatment abolishes the capacity of WT mice to respond to acidosis ([@bib56]), and we propose a role for 5-HT1A-R activity in this response. We show here, for the first time, adverse effects of Fluoxetine on breathing outcomes.

Conclusion {#s2-5}
----------

Previously, a pleiotropic function of Necdin has been reported in different neuronal populations and at different developmental stages. Concerning the 5-HT system, an expression of Necdin was observed in virtually all 5-HT neurons ([@bib57]) and an alteration of the 5-HT system in embryonic and postnatal development was partially described in both *Ndn*-KO (*Ndn^tm1-Stw^*and *Ndn^tm1-Mus^*) mouse models, with alterations in 5-HT axonal bundle projections ([@bib27]; [@bib37]) and 5-HT fibers containing swollen 5-HT 'varicosities' ([@bib37]; [@bib57]). Furthermore, an alteration of 5-HT metabolism ([@bib57]) was observed in mutant neonates suggesting that it might alter 5-HT modulation of the Respiratory Rhythm Generator. Finally, an in vitro exogenous application of 5-HT on brainstem-spinal cord preparations of *Ndn* mutant mice alleviates the incidence of apneas ([@bib37]; [@bib57]). Despite those observations, the pathological mechanism responsible for the serotonopathy in *Ndn*-KO mice and the causal link between this serotonopathy and the breathing alterations were not investigated. Here, we aimed to answer those questions.

Noticeably, all previous studies have been performed on heterozygous *Ndn-*deficient mice, with a deletion of the *Ndn* paternal allele only (*Ndn*+m/-p), the maternal allele being normally silent. However, we have shown that, due to a faint and variable expression of the *Ndn* maternal allele (+m), *Ndn*+m/-p mice present a variability in the severity of respiratory phenotype compared with the *Ndn-/-* mice (here named *Ndn-*KO) ([@bib43]). For instance, reduction of 5-HT neurons was not previously found significant in the *Ndn* + m/-p mice ([@bib57]) but has been found significantly reduced in the *Ndn*-/- mice. In order to avoid such variability and to get consistent results, we chose here to study *Ndn*-/- mice.

Here, we have shown that Necdin plays a pleiotropic role in the development of 5-HT neuronal precursors that guides the development of central serotonergic circuits and the physiological activity of mature 5-HT neurons. Our results suggest that Necdin controls the level of SERT expression in 5-HT neurons and that lack of Necdin increases the quantity and activity of SERT leading to an increased reuptake and intra-cellular accumulation of 5-HT, as visualized by 5-HT LPAs, leading to a reduction in available extracellular 5-HT. Importantly, in vivo inhibition of SERT activity, genetically or pharmacologically (Fluoxetine treatment), is sufficient to prevent the formation of those 5-HT LPAs and suppresses the apnea observed in *Ndn*-KO mice. We also demonstrate, using an ex vivo approach, that the altered chemosensitivity to CO~2~/acidosis is caused by a central 5-HT deficit and is rescued by Fluoxetine-treatment. We conclude that an increase of 5-HT reuptake is the main cause of breathing deficits (central apnea and hypercapnia response) in *Ndn*-KO mice.

Unexpectedly, we reveal an adverse and long-term effect of early life administration of Fluoxetine on the breathing (apneas, chemosensitivity to CO~2~/acidosis) of healthy mice. Previous adverse effects have been observed on anxiety and depression ([@bib15]; [@bib30]) after an early postnatal administration of Fluoxetine but the respiratory deficits are reported here for the first time and should be further investigated in another study.

Respiratory failure in patients with PWS constitute a challenging issue since it is the most common cause of death for 73% of infants and 49% of children, ([@bib9]). Death is often linked to respiratory infection or respiratory disorder and may be sudden, with some reported cases of sudden death occurring at night ([@bib14]). In PWS patients, any environmental acute respiratory challenge caused by, for instance, a respiratory tract infection, high altitude or intense physical activity further exacerbates their inherent disability (blunted response to hypoxima/hypercapnia) to adapt an respiratory response. Until now, the underlying pathology for respiratory failure remained elusive and did not appear to be impacted by recent advancements in treatment modalities ([@bib9]). Although oxygen treatment is efficient in preventing the hypoxemia induced by central apneas ([@bib55]), such treatment is physically constraining. Within the context of PWS, the current study points towards a critical link between Necdin, serotonopathy, and chemosensing, a function in which brainstem serotonergic circuits play a critical role. Since our study shows that Fluoxetine can suppress apnea and restore chemosensitivity, we propose that Fluoxetine might be an appropriate 'acute' treatment that could be considered for Prader-Willi infants/children when they present the first signs of any breathing difficulties.

Materials and methods {#s3}
=====================

Animals {#s3-1}
-------

Mice were handled and cared for in accordance with the Guide for the Care and Use of Laboratory Animals (N.R.C., 1996) and the European Communities Council Directive of September 22th 2010 (2010/63/EU, 74). Experimental protocols were approved by the institutional Ethical Committee guidelines for animal research with the accreditation no. B13-055-19 from the French Ministry of Agriculture. All efforts were made to minimize the number of animals used. Necdin is an imprinted gene, paternally expressed only ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"} and [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). In order to avoid a variability in our results due to a stochastic and faint expression of the maternal allele ([@bib43]), we worked with the *Ndn^tm1-Mus^* strain and decided to study *Ndn*-/- mice (named here *Ndn-*KO), instead of *Ndn*+m/-p mice as it has been done previously.

Fluoxetine was obtained from Sigma (Saint-Quentin Fallavier, France) for cell culture and *en bloc* medullary experiments and from Mylan pharma for in vivo experiments.

Transgenic mice {#s3-2}
---------------

We bred *ePet-EYFP*-expressing ([@bib46]; [@bib47]) or *Slc6a4-Cre* Knock-in ([@bib58]) mice with *Ndn*-KO ([@bib34]) mice, all on C57BL/6 background. Protocols of genotyping mice have been previously described for *Pet-EYFP* ([@bib18]), *Ndn-KO* ([@bib43]) and *Sert*-Cre Knock-in mice ([@bib58]), in which the *Slc6a4* gene was replaced by Cre was referred to in the text as *Slc6a4-*KO. Breeding of *Slc6a4*-KO with *Ndn*-KO mice was referred to in the text as *Ndn-Slc6a4*-DKO.

Immunohistochemistry and quantification {#s3-3}
---------------------------------------

Tissue preparation and IHC were performed as previously described ([@bib43]). Antibodies used were: rabbit polyclonal anti-Necdin (07--565; Millipore, Bedford, MA, USA; 1:500), mouse monoclonal anti-GFP (Interchim, NB600-597; 1:500), goat polyclonal anti-5HT (Immunostar, 20079; 1:300). Sections were examined on a Zeiss Axioplan two microscope with an Apotome module.

Brainstem structures were sampled by selecting the raphe obscurus area and counting was performed on three sagittal sections/animal of 100 µm which represent the entire PET1-YFP positive cell population of the raphe obscurus (ROb/B2) and pallidus (RPa/B1), both nuclei being difficult to separate. For each section, a Z-stack composed of 10 confocal images (8 µm focal spacing) was acquired. For quantification, stereological method has been applied on each Z-stack image using the eCELLence software developed by Glance Vision Technologies (Italy). The total cell number/per animal was obtained by summing the sub-total of cells counted for the 3 Z-stacks.

Images of 5-HT LPAs were acquired using a confocal microscope (Olympus). Between 4 and 8 fibers/brain region for each animal (3WT and 3 KO) were analyzed for the presence of 5-HT LPAs (\>1.8 µm^2^) on 100 µm long fiber. The size of 5-HT LPAs was quantified using Image J. 5-HT LPA diameter has been defined *ad arbitrium* as the size of the largest 5-HT punctiform labelling found in the WT fibers.

Organotypic slice cultures and time lapse experiments {#s3-4}
-----------------------------------------------------

Slice cultures from E11.5 embryonic mouse brainstems were prepared from *Pet-EYFP* and *Ndn KO/Pet-EYFP* mice. Thick coronal sections (250 µm) brainstem were cut using a tissue chopper and cultured in Neurobasal medium (Thermofisher) containing 2% B27 (Thermofisher), 4% horse serum, 10 µg/ml insulin, 200 mM HEPES, 1% Antibiotic Antimycotic (Thermofisher). For time lapse experiments, the dishes were mounted in a CO~2~ incubation chamber (5% CO~2~ at 37°C) fitted onto an inverted confocal microscope (LSM510, Zeiss). Acquisitions of the region containing raphe Pet-EYFP +neurons were performed every 10 min for up to 15 hr. Cell coordinates, velocity, and tortuosity (total length of the track/direct distance from the first to the last point) were calculated using MtrackJ plugin of Image J.

Electrophysiology patch-clamp {#s3-5}
-----------------------------

Sagittal slices that included the raphe (400 μm thick) were cut from brainstems of 2 week old *Pet-EYFP* and *Ndn-KO/Pet-EYFP* mice. Whole-cell recordings were made from YFP+ cells in the region of the B4 raphe nucleus. During recordings, slices were continuously perfused with artificial cerebrospinal-fluid (aCSF) at 37°C. Patch pipettes (4--5 MΩ) were filled with an internal solution with the following composition (in mM): 120 KGlu, 10 KCl, 10 Na~2~-phosphocreatine, 10 HEPES, 1 MgCl~2~, 1 EGTA, 2 ATP Na~2~, 0.25 GTP Na; pH = 7.3 adjusted with KOH. Current clamp at i = 0 were recorded with a HEKA amplifier and acquired using PatchMaster software (HEKA). Offline analysis was performed with Clamfit 10.3.

In vitro recordings from *en bloc* brainstem-spinal cord preparations {#s3-6}
---------------------------------------------------------------------

As previously reported ([@bib7]), the medulla and cervical cord of P0-P1 neonatal mice were dissected, placed in a 2 ml in vitro recording chamber, bubbled with carbogen, maintained at 27°C and superfused (3.5--4.5 ml per min) with aCSFcomposed with (mM): 129.0 NaCl, 3.35 KCl, 21 NaHCO~3~, 1.26 CaCl~2~, 1.15 MgCl~2~, 0.58 NaH~2~PO~4~, and 30.0 D-glucose ('Normal aCSF': pH 7.4) or using the same components except with 10 mM NaHCO~3~ ('Acidified aCSF': pH 7.1). Inspiratory discharges of respiratory motoneurons were monitored by extracellular recording with glass suction electrodes applied to the proximal cut end of C4 and C3 spinal nerves roots. Axoscope software and Digidata 1320A interface (Axon Instruments, Foster, CA, USA) were used to collect electrophysiological data. Offline analysis was performed with Spike 2 (Cambridge Electronic Design, UK) and Origin 6.0 (Microcal Software, Northampton, MA, USA) software for PC. Burst frequency was analyzed and calculated as the number of C4 bursts per minute. The values of inspiratory burst frequency were calculated as the mean of the last 3 min of any condition: ACSF (7.4) and ACSF (7.1). Standardized experiments in WT and *Ndn*-KO preparations were repeated on different preparations from different litters. For a given preparation, only one drug was applied and only one trial was performed.

RT-qPCR {#s3-7}
-------

For RT-qPCR, mice were sacrificed at P1, the brainstem dissected, and tissues were rapidly collected and frozen in liquid nitrogen prior to RNA isolation using standard conditions. RNA, reverse transcription and real time PCR were conducted as previously described ([@bib43]). Sequences of the various primer pairs used for qPCR, as well as the slope of the calibration curve established from 10 to 1 × 10^9^ copies and qPCR efficiency E, were as follow: *Tph2*: F: 5'-GAGCTTGATGCCGACCAT-3'; R: 5'-TGGCCACATCCACAAAATAC-3'; *Slc6a4*: F:5'-CATATGCTACCAGAATGGTGG-3'; R:5'-AAGATGGCCATGATGGTGTAA-3'. For each sample, the number of cDNA copies was normalized according to relative efficiency of RT determined by the standard cDNA quantification. Finally, gene expression was expressed as the cDNA copy number quantified in 5 µL aliquots of RT product.

Western blot {#s3-8}
------------

Newborn mice were sacrificed and brainstems were immediately dissected and snap-frozen in liquid nitrogen and stored at −80°C until protein extraction. Protein extraction was conducted as previously described ([@bib12]). Membranes were blocked with PBS containing 5% BSA for 1 hr, followed by an overnight incubation at 4°C with the following primary antibodies: guinea pig anti-SERT (1/2000, Frontier Institute), mouse anti-B3 tubulin (1/2000, ThermoFisher Scientific). Membranes were then washed and incubated 2 hr with either anti-guinea pig (1/1000, ThermoFisher Scientific), or anti-mouse (1/2000; DAKO) horseradish peroxidase-conjugated secondary antibodies. Visualisation was performed using the Super signal West-pico chemolumniscent substrate (Pierce, Thermo Scientific, France). Quantification was performed using ImageJ.

Biochemical analysis of the medullary serotonergic system {#s3-9}
---------------------------------------------------------

Pregnant mice were killed by cervical dislocation at gestational day E18.5 and fetuses were removed, decapitated, and the medulla dissected and stored at −80°C until measurements. Medullary 5-HT, its precursor L-tryptophan (L-Trp), and its main metabolite, 5-hydroxy-indol acid acetic (5-HIAA), were measured with high-pressure liquid chromatography separation and electrochemical detection (Waters System: pump P510, electrochemical detector EC2465; Atlantis column DC18; mobile phase: citric acid, 50 mM; orthophosphoric acid, 50 mM; sodium octane sulfonic acid, 0.112 mM; EDTA, 0.06 mM; methanol, 5%; NaCl, 2 mM; pH 2.95). Contents are expressed in nanograms per medulla.

Raphe primary neuronal culture and live cell uptake assay {#s3-10}
---------------------------------------------------------

### Raphe primary cell culture {#s3-10-1}

Newborn mice (n = 6 per culture) were decapitated, brainstems extracted, the meninges removed and the medial part of the brainstem dissected. Tissues were enzymatically digested at 37°C for 30 min with HBSS containing 2 mg/mL of filter-sterilized papain. Cells were resuspended in Neurobasal medium (Thermofisher) containing 2% B27 (Thermofisher), 0.5 mM L-glutamine, glucose (50 mM), 50 ng/ml NGF, 10 ng/ml bFGF, 10 µg/ml insulin. 2 × 10^5^ cells were plated on round 14 mm glass coverslip pre-coated with Polyethyleneimine (20 µg/ml). Cells were cultured during 8 days in presence of 5% of NU serum (Becton Dickinson) during the first 2 days. Immunocytochemistry was performed to verify presence of 5-HT^+^ neurons in the culture.

Live cell imaging of (4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP+) uptake {#s3-11}
----------------------------------------------------------------------------------

Cells were placed in a bath chamber on the stage of an inverted microscope (Nikon eclipse TE300) and perfused (2 ml/min) with Krebs medium (mM): 150 NaCl; 2.5 KCl; 2 CaCl~2~; 2 MgCl~2~; 2.5 Hepes acide; 2.5 Hepes-Na; pH 7,4. Time-lapse cell acquisition was started when ASP+ (1, 2, 5, 10, 15 or 20 µM) was added to the perfusion. ASP+ was excited at 488 nm and fluorescence was captured at 607 nm every 10 s for 5 min using Metamorph software (MolecularDevices). Each ASP+ concentration was tested on three different cultures for WT and *Ndn*-KO and one for *Ndn/Slc6a4*-DKO. Cells placed on the coverslip were replaced for each concentration tested. For each ASP+ cells, an ROI of the same surface was delineated on the soma in order to measure pixel intensity in arbitrary fluorescence units. 6 ROI were determined at each measurement. Data were background subtracted and ASP+ fluorescence intensity was expressed as a function of initial fluorescence intensity.

In vivo recordings of breathing parameters by plethysmography {#s3-12}
-------------------------------------------------------------

Breathing of unrestrained, non-anesthetized mice was recorded using constant air flow whole-body plethysmography filled with air or 4% CO~2~ in air (EMKA Technologies, Paris, France). Neonatal mice (P0-P1) were recorded in 25 ml chambers (calibrated by injecting 50 µl of air) maintained at neonatal thermoneutral ambient temperature (32 ± 0.5°C). For adolescent and adult mice (P15-P30-P60), four plethysmography 200 ml chambers containing air or (calibrated by injecting 1 ml of air) maintained at 25 ± 0.5°C were used to allow simultaneous measurements. Analog signals were obtained using an usbAMP device equipped with four inputs and processed using EMKA technologies IOX software (EMKA Technologies, Paris, France). For neonatal mice, we measured mean respiratory frequency (Rf, expressed in cycles per minute) during quiet periods when mice breathed air or 5 min after breathing hypercapnic air. For adolescent and adult mice respiratory parameters (frequency, tidal volume, minute ventilation) were recorded over 30 min after an initial 30 min period of stabilization in the apparatus.,Apnea was defined as a prolonged expiratory time (four times eupneic *expiratory time*), which corresponds to a threshold of 1 s.

Statistical analysis {#s3-13}
--------------------

Analyses were performed using two-tailed non-parametric statistical tools due to the size of the samples (GraphPad, Prism software). Values are indicated as following: (Q2 (Q1, Q3), n; statistical test, p-value) where Q2 is the median, Q1 is the first quartile and Q3 is the third quartile and scatter dot plots report Q2 (Q1, Q3). Histograms report the mean ±SEM. The level of significance was set at a p-value less than 0.05. Appropriate tests were conducted depending on the experiment and are indicated in the figure legends. Mann-Whitney (MW) test was performed to compare two unmatched groups: differences between WT and *Ndn*-KO ([Figure 1](#fig1){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Kolmogorov-Smirnov test was performed to compare the cumulative distribution of two unmatched groups: differences between WT and *Ndn*-KO in apnea accumulation over time ([Figure 3E](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}; [Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}). Chi-square test was performed to compare two groups of animal (WT and *Ndn*-KO) with categorical outcome variable (apnea or no apnea) ([Figure 3C](#fig3){ref-type="fig"}; [Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). Kruskal-Wallis (KW) followed by a post hoc test Dunn test was performed to compare three or more independent groups ([Figure 2G,H](#fig2){ref-type="fig"}; [Figure 3D,F--H](#fig3){ref-type="fig"}); Friedman test followed by a post hoc test Dunn test was performed to compare matched groups ([Figure 4---figure supplement 2C,D](#fig4s2){ref-type="fig"}). Two-way ANOVA followed by Bonferroni post-hoc test was performed to compare two factors ([Figure 2B](#fig2){ref-type="fig"}). Two-way repeated-measure (RM) ANOVA was performed to compare two factors (genotype compared either to time, drug treatment or respiratory challenge) with repeated measure matched by time or respiratory challenge ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}; [Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"};[Figure 4D--F,L](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}); genotype and respiratory challenge. ANCOVA was performed to compare slopes of two regression lines (WT *versus Ndn*-KO: [Figure 2E](#fig2){ref-type="fig"}). \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Necdin shapes serotonergic development and SERT activity modulating breathing in a mouse model for Prader-Willi Syndrome\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Joseph Gleeson as Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers and editors appreciated that the work clearly demonstrated the respiratory defect in mouse pups lacking necdin is an increase in SERT activity, and that inhibiting SERT could be a therapeutic approach for Prader Willi patients. Overall this is an interesting study with therapeutic possibilities for Prader-Willi and other disorders featuring respiratory suppression with insensitivity to hypoxia/hypercapnia.

Summary:

Matarazzo and colleagues investigate the respiratory system in mice deficient for necdin, as a model for neonatal respiratory deficits present in children with Prader Willi Syndrome. They report that lack of necdin disturbs the migration of serotonin neuronal precursors and the morphology of serotonergic neurons. In these mice, either deletion of the serotonin transporter (Sert) or treatment with fluoxetine, a SERT reuptake inhibitor, restores normal breathing. They propose that the respiratory defect in mouse pups lacking necdin is an increase in SERT activity, and that inhibiting SERT could be a therapeutic approach for Prader Willi patients.

In general, this is a well designed, implemented, and written body of work that develops insight into the development of breathing abnormalities in Prader-Willi and other disorders featuring respiratory suppression with insensitivity to hypoxia/hypercapnia and suggests potential treatment for these problems.

Essential revisions:

1\) The histological analysis does not indicate enough specifics on how quantification was performed, notably it does not appear that stereological methods were utilized. In the absence of such methods there are significant concerns for bias.

2\) The authors focus on the serotonin system and the effect of modulating the 5-HT system genetically or pharmacologically. Previous studies have shown that other excitatory neuromodulators (Substance P and TRH) likewise partially rescue the respiratory deficit in brainstem-spinal cord preparations from Ndn-KO mouse pups (Pagliardini Advances in Experimental Medicine and Biology 2008). This raises the possibility that the serotonergic deficit is only one of many deficits in this genetic mutant. This point should be addressed and weighed in light of previous publications.

3\) The study would have much higher impact if the truly novel findings were disentangled from replication of previous results, although this replication is also important to report. The authors fail to place their experiments in the context of previously published work, in some cases contradicting their own previous studies (e.g. number of 5_HT neurons, (Zanella, 2008)) but confirming that of others (Pagliardini, 2005) with no reference to either study. This will put undue strain on readers to identify which are new observations and which are repeats of previously published observations.

4\) The abnormality of serotonergic function in the respiratory system in the hindbrain of Ndn-null mice has been studied by several groups over the last decade, compromising the novelty of the study. For example, the authors neglect to reference key publications: the papers from the Yoshikawa group about the discovery of mouse necdin, their necdin knockout mouse and work on neuronal abnormalities consequent to lack of necdin; the papers from the Wevrick group on the discovery of human necdin, the disruption of serotonergic axonal projections in necdin null mice, their discovery that serotonergic neurons in the hindbrain of necdin-null mice have abnormal cytoarchitecture and abnormal varicosities; the migration defect in necdin-deficient neurons; and the author\'s own work showing 5-HT abnormalities by HPLC (Zanella Advances in Experimental Medicine and Biology 2008) and the effect of fluoxetine in WT mice (Voituron, 2010). The authors should re-write these parts of the manuscript to better summarize key previous work, and put their new findings in this context.

\[Editors\' note: the manuscript was rejected after revisions, but the authors were invited to make a new submission.\]

Thank you for submitting your work entitled \"Necdin shapes serotonergic development and SERT activity modulating breathing in a mouse model for Prader-Willi Syndrome\" for consideration by *eLife*. Your article has been reviewed by one of the original peer reviewers from the first submission, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewer opted to remain anonymous.

Our decision has been reached after consultation between the editors and the reviewer. Based on these discussions and the individual review below, we regret to inform you that your work will not be considered further for publication in *eLife* at this time. Because *eLife* does not permit two rounds of review, the editors have rejected this paper. If you and your co-authors feel you can address the issues as requested, you can then submit a new manuscript, which will be considered in light of the previous review.

The reviewers appreciate the importance of the work, and the insight provided by the pharmacological and genetic manipulations of the serotonin pathway to understand the modulation of breathing in this mouse model for Prader-Willi Syndrome, but there remained serious concerns that the text was not adequately revised to take into account the previous literature, and to correct errors in English. As described by the reviewer below, the use of a homozygous rather than in imprinted model is not sufficient to claim that the results are novel. With these concerns, and others raised by the reviewer, the team is concerned that readers will miss the importance of the work.

*Reviewer \#2:*

The authors have responded to the original review primarily by adding a sentence at the end of each section describing how their work repeats and extends, to a greater or lesser extent, work previously done by others. Furthermore, they state that the work is all novel because they now use homozygous null mice rather than paternally inherited heterozygous mice. This makes the Results section very awkward and difficult to follow. It remains unclear which experiments provide truly novel data and which a confirmation of their work and that of others. Once the previously demonstrated findings are subtracted from the results, the novel results may become apparent. The manuscript can then be properly assessed for its suitability for publication, if the truly novel results are of sufficient interest. In summary, the authors need to rewrite the entire manuscript to describe what is already known about the serotonergic system in necdin +/- and necdin KO mice, then state their novel results.

The manuscript also has many awkward phrases that make it difficult to read. In the Abstract alone, they need to edit, for example:

· "Necdin-deficient mouse is the best relevant model" -- awkwardly phrased.

· "Increase of 5-HT reuptake activity of the Serotonin Transporter (SERT)" -- I don\'t think that was demonstrated by the experiments shown as they measured SERT transport in [Figure 2](#fig2){ref-type="fig"}, not reuptake.

· "Or fluoxetine treatment, a SERT inhibitor reuptake" -- what is a SERT inhibitor reuptake?

· "Is sufficient to cause respiratory deficit in Necdin-KO pups" -- this is vague.

· "SERT inhibition is a therapeutic perspective for PW patients" -- what does therapeutic perspective mean, and why PW and not PWS is defined earlier in the same paragraph?

The rest of the manuscript has similar issues with awkwardly phrased and ungrammatical English that makes it difficult to interpret.

10.7554/eLife.32640.024

Author response

> Essential revisions:
>
> 1\) The histological analysis does not indicate enough specifics on how quantification was performed, notably it does not appear that stereological methods were utilized. In the absence of such methods there are significant concerns for bias.

Effectively, we didn't explain our method of quantification in the text. Now, we introduced this explanation in the Material and methods in the Immunohistochemistry and quantification part as following:

"Brainstem structures were sampled by selecting the raphe obscurus area and counting was performed on 3 sagittal sections of 100µm/animals which represent the entire PET1-YFP positive cell population of the raphe obscurus (ROb/B2) and pallidus (RPa/B1), both nuclei being difficult to separate. For each section, a Z-stack composed of 10 confocal images (8 µm focal spacing) was acquired. For quantification, stereological method has been applied on each Z-stack image using the eCELLence software developed by Glance Vision Technologies (Italy). The total cell number/ per animal was obtained by summing the sub-total of cells counted for the 3 Z-stacks."

> 2\) The authors focus on the serotonin system and the effect of modulating the 5-HT system genetically or pharmacologically. Previous studies have shown that other excitatory neuromodulators (Substance P and TRH) likewise partially rescue the respiratory deficit in brainstem-spinal cord preparations from Ndn-KO mouse pups (Pagliardini Advances in Experimental Medicine and Biology 2008). This raises the possibility that the serotonergic deficit is only one of many deficits in this genetic mutant. This point should be addressed and weighed in light of previous publications.

This point is extremely relevant. The reasons why, in regards to the respiratory distress, we studied the 5-HT neurons and system are: 1) previously we showed that Necdin is not expressed in the NKR1 positive neurons of the preBötzinger complex ((Zanella et al., 2008b); Figure S3), excluding a cell autonomous alteration of those cells; 2) Necdin is expressed in medullary 5HT neurons and Necdin deficiency in medullary preparations of *Ndn*-KO neonates alters the serotonergic modulation of the inspiratory rhythm generator (Zanella et al., 2008b), 3) Abnormal projections of 5-HT fibers toward both the rostral CNS and the RVLM were previously reported in *Ndn-*KO (Lee et al., 2005; Pagliardini et al., 2005). In addition, differences in the morphology of 5-HT vesicles from medullary fibers in sections performed at the level of the pre-Bötzinger complex were observed (Pagliardini et al., 2005; Zanella et al., 2008b). 4) Substance P, TRH and 5-HT are excitatory neuromodulators acting in part on the preBötzinger Complex to increase the frequency and stabilize inspiratory burst generation (Teran et al., 2015); both Substance P and TRH increase the frequency of inspiratory bursts and decrease the incidence of irregularly rhythm in brainstem-spinal cord preparations from *Ndn*-KO mouse pups (Pagliardini et al., 2005; Pagliardini et al., 2008). However, most substance P and TRH inputs to the preBötzinger complex come from the medullary 5-HT neurons (Hodges et al., 2008b; Holtman et al., 1994; Kachidian et al., 1991; Ptak et al., 2009).

While we agree with the reviewers that the 5-HT system is not the only one affected in *Ndn*-KO mice, the specific point raised here actually further emphasizes the critical role of 5-HT neuron alterations in driving respiratory rhythm perturbation in *Ndn*-KO mice. Furthermore our results also show that increase of extracellular 5-HT level alone is sufficient to restore eupneic breathing.

Consequently, in order to clarify this point, in the Introduction of our article, we included:

"Furthermore, it was previously shown that, in perinatal *Ndn*-KO mice in vitro, an irregular inspiratory rhythm and apneas resulted from an alteration in the regulation of the Inspiratory Rhythm Generator (IRG) (Ren et al., 2003; Zanella et al., 2008). 5-HT application, as well as other neuromodulators such as substance P and thyrotropin-releasing hormone (TRH), stabilized the inspiratory rhythm and reduced the incidence of apneas (Pagliardini et al., 2005; Zanella et al., 2008). Interestingly, 5-HT neurons co-release substance P and TRH, and represent the main source of these peptides to the IRG (Hodges et al., 2008; Holtman et al., 1994; Kachidian et al., 1991; Ptak et al., 2009). An anatomical study of the developing *Ndn*-KO medulla reported alterations in the majority of axonal tracts within the medulla and in particular an abnormal morphology and orientation of 5-HT and Substance P axonal fibers (Pagliardini et al., 2005; Pagliardini et al., 2008)."

> 3\) The study would have much higher impact if the truly novel findings were disentangled from replication of previous results, although this replication is also important to report. The authors fail to place their experiments in the context of previously published work, in some cases contradicting their own previous studies (e.g. number of 5_HT neurons, (Zanella, 2008)) but confirming that of others (Pagliardini, 2005) with no reference to either study. This will put undue strain on readers to identify which are new observations and which are repeats of previously published observations.

Because we submitted the paper as a Short Report which has space limitation, we have not placed our experiments and results in the precise context of previously published work, including authors' publications. Now, we introduced in our revised manuscript (see point 2) pioneer studies conducted in the Necdin mutant mouse that highlighted respiratory deficits and dysfunction of neuromodulation such as the 5-HT system (mainly by R. Wevrick's and Muscatelli's teams); however we knew neither the cause nor the consequences of this dysfunction. In our current study, our aim was to investigate the development and functional maturation of the 5-HT system since we first showed that Necdin is expressed in post-mitotic 5-HT precursors (in this paper) and throughout embryonic and postnatal development of 5-HT neurons. To conduct a rationale and complete investigation, we had to replicate experiments in the mouse model in order to make a complete story on deciphering causal link between 5-HT alteration and respiratory deficits in the same mouse model. Indeed some 5-HT linked alterations were previously described in different Ndn-KO models (different KO constructs, different genetic background, homozygous versus heterozygous mutants) and by different teams.

In this article we studied homozygous mutants (-/-) named here *Ndn*-KO. Necdin is an imprinted gene paternally expressed only, the maternal allele being silent. Previously we have shown that Necdin mice deleted for the paternal allele only (Ndn +m/-p) presented a milder phenotype than the *Ndn*-/- (deleted for both paternal and maternal alleles) due to a stochastic and faint expression of the maternal allele (Rieusset et al., 2013). This unexpected expression was the cause of a high variability in the severity of the phenotype that might result in not significant differences compared with the wild-type mice. To avoid this variability, we chose here to study the -/- *Ndn* mice.

To clarify this point we propose to add in the text, introduction of the Results/Discussion part:

"Necdin is an imprinted gene, paternally expressed only. In order to avoid a variability in our results due to a stochastic and faint expression of the maternal allele (Rieusset et al., 2013), here, we chose to work on *Ndn*-/- mice (named here *Ndn-*KO) instead of *Ndn* +m/-p mice as it has been done previously (Zanella et al., 2008)."

Importantly, the experiments we made in our first publication (Zanella et al., 2008) were performed on *Ndn*+m/-p mice named in the article *Ndn-*KO mice. Then in the review written by Zanella (Zanella et al., 2008b) based on the study published in Journal of Neurosciences, the *Ndn*-KO were cited as *Ndn* -/- instead of *Ndn*+m/-p; this was an error in the review.

If we consider the experiments performed on 5-HT neurons/system "which are repeats of previously published observations", they are restricted to:

1\) In the first paragraph entitled "Lack of Necdin affects the development and function of 5HT neurons":

-- Necdin expression in 5-HT neurons by immunohistochemistry (using a specific antibody validated on *Ndn*-/- brain sections) was already reported in Zanella et al. (Zanella et al., 2008). However here we precisely defined the extent of expression in the 5-HT neurons of the different raphe nuclei throughout embryonic and post-natal stages, showing for the first time that Necdin is expressed in 5HT post-mitotic precursors [Figure 1---figure supplement 1A-I](#fig1s1){ref-type="fig"}.

-- Alteration of 5HT projections have been observed by Pagliardini et al. (2008). This study is now cited in the Introduction. Here we observed a similar alteration illustrated in [Figure 1---figure supplement 1J](#fig1s1){ref-type="fig"}. We modified the text as following:

"While 5-HT neuronal somas from rostral midbrain project theirs axons to the mesencephalon at E12.5, in *Ndn*-KO embryos, we observed a decrease in those ascending 5-HT projections ([Figure 1---figure supplement 1J](#fig1s1){ref-type="fig"}) as previously described (Pagliardini et al., 2008)."

-- The counting of 5-HT neurons in *Ndn*-KO pups ([Figure 1 B-C](#fig1){ref-type="fig"}).

Concerning the number of 5-HT neurons, to explain why "in some cases contradicting their own previous studies (e.g. number of 5-HT neurons, (Zanella, 2008) but confirming that of others (Pagliardini, 2005) with no reference to either study". As explained above, *Ndn*+m/-p presented a milder phenotype than the *Ndn*-/- (deleted for both paternal and maternal alleles) due to a stochastic and faint expression of the maternal allele (Rieusset et al., 2013). In particular in this previous article (Rieusset et al., 2013), we showed that the number of 5HT neurons in the *Ndn*+m/-p is not significantly different compared to wild-type, as we already observed in the publication of Zanella et al., 2008. However, in *Ndn*-/- mice we observed a marked reduced number of 5-HT neurons (Rieusset et al., 2013). Here, by counting the Pet1eYFP+ neurons in *Ndn*-/- we confirmed the results and variability described in Rieusset et al., 2013. We clarified this point in the text as following:

"At E16.5, we observed a lack of organization of the 5-HT cytoarchitecture in *Ndn-*KO with misplaced 5-HT neurons leading in neonates to a significant \~30% reduction in the total number of 5HT-expressing neurons as quantified in the B1-B2 caudal Raphe nuclei ([Figure 1 B-C](#fig1){ref-type="fig"}); we already observed such a significant reduction in *Ndn*-/- mutants but not in *Ndn*+m/-p mutants (Rieusset et al., 2013)."

We modified the conclusion of this paragraph as following:

"Overall, our results showthat Necdin is critical for the establishment and functional features of 5-HT neurons during development."

2\) In the second paragraph entitled "Lack of Necdin increases the expression and activity of serotonin transporter SERT":

-- Neurite abnormalities with the presence of abnormal 5-HT vesicles/varicosities were observed in 5HT fibers (Pagliardini, 2005 and Zanella, 2008). In fact, we couldn't prove that those abnormal 5-HT vesicles are either varicosities defined as "swellings that release their neurotransmitters at neuroeffector junctions" or spheroids defined as "dystrophic degenerative structures". That is the reason why we named them here enLarged Punctiform Axonal (LPA) 5-HT staining. Furthermore, for the first time, we quantified them in different brain regions and in different genetic mutant mice (Ndn KO, Sert KO, Ndn/Sert DKO). We modified the text as following:

"An alteration of 5-HT metabolism was already observed in *Ndn*-KO mice (Zanella et al., 2008), along with abnormal 5-HT fibers with "large varicosities "(Pagliardini et al., 2005; Zanella et al., 2008). Using immunohistochemistry (IHC), we quantified these enlarged punctiform axonal (LPA) 5-HT staining, showing a significant increase in different *Ndn-*KO brain regions compared with WT ([Figure 2A-B](#fig2){ref-type="fig"})."

3\) In the third paragraph entitled "Genetic ablation or pharmacological inhibition of SERT uptake restores normal breathing in *Ndn-*KO mice".

-- We reported in a previous publication that in wild type mice: "Fluoxetine Treatment Abolishes the in vitro Respiratory Response to Acidosis in Neonatal Mice" (Voituron et al., 2010). Here, since we investigated the effect of fluoxetine in *Ndn*-KO, the experiments in control animals was mandatory.

We modified the text as following:

"Looking at the chemosensitive response to central acidosis in *en bloc* brainstem-spinal cord, we found that fluoxetine treatment abolished the capacity of WT to respond to acidosis as we previously observed (Voituron et al., 2010) ([Figure 4---figure supplement 2A-D](#fig4s2){ref-type="fig"})."

All the other experiments of this paper "are new published observations".

> 4\) The abnormality of serotonergic function in the respiratory system in the hindbrain of Ndn-null mice has been studied by several groups over the last decade, compromising the novelty of the study. For example, the authors neglect to reference key publications: the papers from the Yoshikawa group about the discovery of mouse necdin, their necdin knockout mouse and work on neuronal abnormalities consequent to lack of necdin; the papers from the Wevrick group on the discovery of human necdin, the disruption of serotonergic axonal projections in necdin null mice, their discovery that serotonergic neurons in the hindbrain of necdin-null mice have abnormal cytoarchitecture and abnormal varicosities; the migration defect in necdin-deficient neurons; and the author\'s own work showing 5-HT abnormalities by HPLC (Zanella Advances in Experimental Medicine and Biology 2008) and the effect of fluoxetine in WT mice (Voituron, 2010). The authors should re-write these parts of the manuscript to better summarize key previous work, and put their new findings in this context.

We agree with this comment. This point is somehow linked to point 2 and 3 and the modifications made to answer those both points should also be considered in point 4. Indeed, we tried to introduce all the key previous work in different parts of the text: Introduction, Results and Discussion. All the studies and publications cited by the reviewers have been now introduced. The publication (book review) of Zanella et al. in Advances in Experimental Medicine and Biology 2008 has been replaced by the original study: Zanella et al., 2008.

\[Editors\' note: what now follows is the author responses after they submitted for further consideration.\]

> \[...\] Reviewer \#2:
>
> The authors have responded to the original review primarily by adding a sentence at the end of each section describing how their work repeats and extends, to a greater or lesser extent, work previously done by others.

We actually modified considerably all parts of the manuscript. We introduced and discussed previous literature, in order to better contextualize our results. In the Introduction, we extended the description of breathing deficits in PWS patients, and the previous results obtained on *Ndn*-KO mice linked to the breathing deficits. We also extended the conclusion, starting by summarizing the previous results published on Necdin, 5-HT and breathing in order to discriminate our novel results from those previous results. We explained how and when Fluoxetine might be used in PWS patients to alleviate their breathing deficits. We also modified the Material and methods section providing more explanations on the use of Malgel2-/- mice (see next paragraph). In the present version, we have also included 25 new references (compared to the initial version). In the previous version, there were some novel results described in the figure legends but not in the main text. In the present version, we thus transferred this information from the figure legends to the result part.

> Furthermore, they state that the work is all novel because they now use homozygous null mice rather than paternally inherited heterozygous mice.

We never made such a claim and we apologize for this misunderstanding: the novelty aspect of our study is discussed compared to the literature in the Results/Discussion and conclusion sections, and never refers to the use of heterozygous vs. homozygous mice. The use of homozygous mice allowed us to reduce the variability in the severity of their phenotype (apnea). Indeed, we previously observed that heterozygous mice show an important phenotypic variability, ranging from strong to light phenotypic alteration, due to a stochastic expression of the maternal allele (Rieusset et al., 2013). Here, the use of homozygous mice is justified scientifically and ethically, as it allowed us to get significant results using a smaller number of mice, since their phenotype (apnea in particular) was of greater homogeneity. We explained why we used homozygous rather than heterozygous mice in the "Material and Methods" part, which is the most appropriated section, avoiding any misunderstanding concerning the novelty of our results (such as considering that the novelty is the use of Ndn-/- mice).

> It remains unclear which experiments provide truly novel data and which a confirmation of their work and that of others. Once the previously demonstrated findings are subtracted from the results, the novel results may become apparent.

In order to clarify this point, we made a table listing all figures (see table below) indicating which precisely are the repeated and novel experiments, the references of the repeated experiments and the justification to repeat them. Less than 10% of experiments have been replicated, consequently more than 90% are novel.

> The manuscript can then be properly assessed for its suitability for publication, if the truly novel results are of sufficient interest. In summary, the authors need to rewrite the entire manuscript to describe what is already known about the serotonergic system in necdin +/- and necdin KO mice, then state their novel results.

Indeed, 90% of the results presented in this article are novel results that have never been published in neither heterozygous nor homozygous *Necdin*-KO mice. In the new version, novel results are clearly stated in the Abstract and in the conclusion ("Here, we showed...healthy mice."). In the "Results and Discussion" part we also present our results with respect to the previous ones.

Overall, we hope that the readers will see the novelty of our results, listed below:

-- The expression of Necdin in early post-mitotic precursors (expressing Pet1) followed by an expression in all 5-HT neurons;

-- The misplacement and disorganization of 5-HT raphe nuclei in *Ndn*-KO mice. The decrease in the number of 5-HT neurons in the B1-B2 nuclei, a result not previously observed in our *Ndn*+m/-p mice but observed in *Ndn*-/- mice and we explained why (see table);

-- An in vivo alteration in cell migration of 5-HT precursors;

-- An alteration of firing properties of 5-HT neurons recorded on brain slices of mutant;

-- The quantification of enlarged Punctiform Axonal (LPA) 5-HT stainings in different brain regions and in different genetic backgrounds (WT, *Ndn*-KO, *Slc6a4* and *Ndn/Slc6a4*-DKO) showing the lack of Sert expression is sufficient to suppress the 5-HT LPA stainings;

-- The overexpression of Sert resulting from a post-transcriptional or post-traductional regulation and resulting in an increase activity of SERT transport and uptake (indeed the experiment using ASP+ allows the visualization and quantification of ASP+ uptake through SERT (Lau et al., 2015));

-- The genetic ablation of *Slc6a4* (encoding SERT) in *Ndn*-KO (*Ndn/Slc6a4*-DKO) leading to a rescue of the phenotype (normalization of apnea and loss of accumulation of 5-HT in LPAs);

-- The in vivo positive effect of early Fluoxetine treatment in *Ndn*-KO mice allowing apnea to be normalized;

-- The in vivo adverse effect of early Fluoxetine treatment in WT mice, inducing apnea. We are not aware of any published or unpublished similar results and so considered that they are novel.

> The manuscript also has many awkward phrases that make it difficult to read.

We are really sorry for the grammatical errors (this article was written by French scientists). The new manuscript has been read and corrected by Pr. Keith Dudley (a native English scientist) and Dr Simon McMullan (Australian Senior scientist).

> In the Abstract alone, they need to edit, for example:
>
> "Necdin-deficient mouse is the best relevant model" -- awkwardly phrased.

Now replaced by: *"*The *Necdin*-deficient ouse is the only model...".

> "Increase of 5-HT reuptake activity of the Serotonin Transporter (SERT)" -- I don\'t think that was demonstrated by the experiments shown as they measured SERT transport in [Figure 2](#fig2){ref-type="fig"}, not reuptake.

We agree that the reuptake is not appropriated. However uptake is the appropriate word since we measure in [Figure 2E-H](#fig2){ref-type="fig"} (and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) the SERT uptake activity using ASP+ as fluorescent substrate and we measured the kinetic parameters of Asp+ uptake in primary cultures of raphe neurons. Indeed those experiments measure SERT transport activity and the uptake activity (Lau et al., 2015).

> "Or fluoxetine treatment, a SERT inhibitor reuptake" -- what is a SERT inhibitor reuptake?

This was a big mistake that we didn't see. Of course it has been corrected by: a 5-HT reuptake inhibitor.

> "Is sufficient to cause respiratory deficit in Necdin-KO pups" -- this is vague.

This has been replaced by: is sufficient to cause the apneas in *Necdin-*KO pups.

> "SERT inhibition is a therapeutic perspective for PW patients" -- what does therapeutic perspective mean, and why PW and not PWS is defined earlier in the same paragraph?

This has been replaced by:and that Fluoxetine opens a novel perspective to improve ventilator control in patients with PWS.

> The rest of the manuscript has similar issues with awkwardly phrased and ungrammatical English that makes it difficult to interpret.

We have modified the Abstract, and the text has been proofread and corrected by Pr. Keith Dudley (a native English speaking scientist) and Dr. Simon McMullan (Australian Senior scientist), as mentioned above.

Experiments:\
referenced figuresNovel or Replicate experiment (article reference if replication)Comments[Figure 1A](#fig1){ref-type="fig"}NovelExpression of Necdin in 5-HT neuronal precursors has never been shown[Figure 1B](#fig1){ref-type="fig"}NovelSuch disorganization when the 5-HT nuclei should be set up was not reported in any previous publication.[Figure 1C](#fig1){ref-type="fig"}Replicate (Zanella et al., 2008; Rieusset et al; 2013)The number of 5-HT neurons has been counted in the *Ndn -/-* mice studied in this article. Previously (Zanella, 2008) we showed that in *Ndn+m/-p* mice, the number of 5-HT neurons was not significantly reduced compared with WT. However we showed that Ndn +/-p mice present a high variability in the severity of the phenotype, cellular defects due to a stochastic and faint expression of the maternal allele in some mice. To avoid this variability we chose to study *Ndn-*/- mice.[Figure 1D](#fig1){ref-type="fig"}NovelIt's the first time that defects in radial migration of *Ndn*-deficient 5-HT precursors are shown *in vivo* using twophoton time-lapse imaging. Furthermore, our study revealed a problem of somal translocation. Problems of migration of other neuronal populations in *Ndn-*KO mice have been suggested but never shown *in vivo*.[Figure 1E](#fig1){ref-type="fig"}Novel[Figure 1F](#fig1){ref-type="fig"}Novel[Figure 1G](#fig1){ref-type="fig"}Novel[Figure 1H](#fig1){ref-type="fig"}Novel[Figure 1I](#fig1){ref-type="fig"}NovelElectrophysiological recordings of 5-HT neurons in *Ndn-KO* mice have never been reported.[Figure 1J](#fig1){ref-type="fig"}Novel[Figure 1K](#fig1){ref-type="fig"}Novel[Figure 1---figure supplement 1 A-I](#fig1s1){ref-type="fig"}NovelThis panel shows (for the first time) the expression of Necdin in Pet-EYFP 5-HT precursors at E10.5. Then we show that Necdin is expressed in all 5-HT neurons in raphe nuclei. Again, the expression of Ndn by immunohistochemistry in all 5-HT raphe nuclei has never been shown (only suggested in Zanella).[Figure 1J](#fig1){ref-type="fig"}Replicate (Lee et al., 2005)Indeed, we looked at the distribution of 5-HT neurons in *Ndn*-KO mice at nearly all development stages; we chose to show the E12.5 and E16.5 because they suggest a delay in migration. Previously, Lee et al. showed a similar defect at E12.5, in their *Ndn*- KO model, proposing a defect in serotonergic projections reflecting a more general delay or dysfunction of axonal projections. We think that it is important to show that this defect is present in both *Ndn*-KO mouse models.[Figure 2A-2B](#fig2){ref-type="fig"}NovelThe abnormal 5-HT fibers with "large varicosities "were previously described (Pagliardini et al., 2005; Zanella et al., 2008). The novelty here is: the quantification in different brain structures of the 5-HT LPAs and, importantly the fact that we show that those 5-HT LPAs disappear in *Ndn/Slc6a4*-DKO (normal labelling being present in *Slc6a4*-KO mice).[Figure 2C-2D](#fig2){ref-type="fig"}All NovelsThe quantification of SERT in *Ndn*-KO has never been done until this study.[Figure 2E-2H](#fig2){ref-type="fig"}All NovelsASP+uptake assays in *Ndn*-KO serotonergic cells (primary cultures of raphe) compared with WT and SERT-KO (negative control) cells have never been done previously. This experiment allows to assess the activity of SERT as a transporter leading to an uptake of ASP+.[Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}NovelL-Trp quantification (5-HT substrate) has never been done in Ndn-KO mice.[Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}Replicate (Zanella et al., 2008)5-HT and 5-HIAA were previously quantified in *Ndn*+m/-p. It was necessary to quantify them here in the *Ndn*-/- animals and to include those quantifiactions in a more complete analysis of the 5-HT system.[Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}Novel*Tph2* transcripts have not been quantified previously.[Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}All Novels*Slc6a4* (Sert) tanscripts have not been quantified previously.[Figure 2---figure supplement 2A - 2B](#fig2s2){ref-type="fig"}All NovelsIllustration of the ASP+ uptake in the 5- HT neurons.[Figure 3A-3H](#fig3){ref-type="fig"}All novelsPlethysmography recordings and breathing parameters analysis of *in vivo* Fluoxetine treatment in early life of Necdin deficient mice or Ndn/Sl6a4 DKO mice in comparison with Ndn-KO or WT mice. Recordings are performed at P15 (O DAT) after a 10 days treatment with Fluoxetine.[Figure 3---figure supplement 1A to H](#fig3s1){ref-type="fig"}All novelsSimilar experiments as performed in [Figure 3](#fig3){ref-type="fig"} but performed at 15 DAT and 30 DAT in order to assess a mid/long term effect of fluoxetine treatment.[Figure 3---figure supplement 2A to E](#fig3s2){ref-type="fig"}All novels[Figure 4 A to L](#fig4){ref-type="fig"}All novels*In vivo* **hypercapnia** and *in vitro* acidosis have never been assessed either in *Ndn*KO mice or in *Ndn-*KO brainstem-spinal cord preparations treated or not with fluoxetine. In our previous study (Zanella et al., 2008) **hypoxia** only was assessed.[Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}All novels8-OH-DPAT on *Ndn*-KO brainstem-spinal cord *in vitro* preparations has never been assessed previously.[Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}Novel experiment: treatment with 8-OHDPAT Replicate experiment: acidosis in WT preparations treated or not with fluoxetine (Voituron et al., 2010)In 2010, Voituron et al. showed that "Fluoxetine Treatment Abolishes the In Vitro Respiratory Response to Acidosis in Neonatal Mice". In our study, since we investigated the effect of fluoxetine in *Ndn*-KO brainstem-spinal cord preparations submitted to acidosis, the experiments in control animals were mandatory and are presented in this figure. Here, we added a novel experiment in control mice: the effect of 8-OH-DAPT.

[^1]: These authors contributed equally to this work.
